Loading clinical trials...

Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury. | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.

Risedronate for Prevention of Osteoporosis After Spinal Cord Injury

NCT00150696•Toronto Rehabilitation Institute

Summary

The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.

Eligibility

Age

16 - 60 years

Sex

ALL

Healthy Volunteers

•Bilateral knee flexion contractures.
•Pregnant, lactating or post-menopausal females.
•Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.
•Treatment in the last year with calcitonin, fluoride or anabolic steroid.
•Concurrent treatment with prednisone.

Locations (2)

Hamilton Health Sciences, Chedoke Site

Hamilton, Ontario, Canada

Toronto Rehab, Lyndhurst Centre

Toronto, Ontario, Canada

Key Dates

Start Date

February 1, 2000

Completion Date

November 1, 2005

Last Updated

November 21, 2007

Enrollment

Estimated participants

Conditions

Acute Spinal Cord Injury.

Interventions

Risedronate

DRUG